{'fraction_non_alphanumeric': 0.02930056710775047, 'fraction_numerical': 0.034026465028355386, 'mean_word_length': 5.4573170731707314, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Induction of Humoral and Cell‐Mediated Immune Responses by a Novel Adjuvant Derived From HumanAnaphylatoxin C5a

C5a enhances both humoral and cell‐mediated immunity as well as inflammation. We have developed two molecular adjuvant (MA) analogs based on the C‐terminal region of human C5a [EP67: YSFKDMP(MeL)aR and EP54: YSFKDMPLaR] that trigger immunity. When conjugated to either peptide or whole protein antigen, these analogues enhance both humoral and cell‐mediated immunity in vitro and in vivo. The antibody response induced by a MA‐peptide antigen construct differs from that of a conventional adjuvant (CFA) in that the response is mainly IgG2a and IgG2b. Protein antigen conjugated to EP67 induces a high‐titer mix of IgG1, IgG2a, and IgG2b antibodies. In contrast, OVA induces an IgG1 antibody response. In vitro stimulation of spleen cells derived from EP67‐antigen injected mice produced an enhanced T cell proliferation response compared to mice immunized with antigen alone. This work was supported by Grants Ag09948‐09, AG031496, and AI065712